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Edited by Veli-Pekka LehtoAbstract We have previously shown that Rap1 as well as its
guanine nucleotide exchange factor Epac1 increases cell–cell
junction formation. Here, we show that activation of Epac1 with
the exchange protein directly activated by cAMP (Epac)-speciﬁc
cAMP analog 8CPT-2 0O-Me-cAMP (007) resulted in a tighten-
ing of the junctions and a decrease in the permeability of the
endothelial cell monolayer. In addition, 007 treatment resulted
in the breakdown of actin stress ﬁbers and the formation of cor-
tical actin. These eﬀects were completely inhibited by siRNA
against Epac1. In VE-cadherin knock-out cells Epac1 did not af-
fect cell permeability, whereas in cells re-expressing VE-cad-
herin this eﬀect was restored. Finally, the eﬀect of Epac
activation on the actin cytoskeleton was independent of junction
formation. From these results we conclude that in human umbil-
ical vein endothelial cells Epac1 controls VE-cadherin-mediated
cell junction formation and induces reorganization of the actin
cytoskeleton.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Exchange protein directly activated by cAMP (Epac) repre-
sents a small family of two guanine nucleotide exchange fac-
tors (GEFs) for the small GTPases Rap1 and Rap2. Epac1
and Epac2 are activated by direct binding of cAMP and ele-
vated levels of cAMP result in the activation of both Rap1
and Rap2 in cells that do express Epac1 and/or Epac2. The
analysis of the function of these proteins was greatly facilitated
by the development of a cAMP analog, 8CPT-2 0O-Me-cAMP
(007), speciﬁc for Epac1 and Epac2 [1]. This analog does not
activate other cAMP targets, i.e., protein kinase A (PKA)
and ion channels. Using this analog it was found that Epac
functions, among others, in integrin-mediated adhesion, cal-
cium-induced calcium release and subsequent insulin secretion,
activation of phosphoinositol-3-kinase, protein kinase B and
activation of phospholipase C epsilon (reviewed in [2]). MoreAbbreviations: HUVEC, human umbilical vein endothelial cells; Epac,
exchange protein directly activated by cAMP; PKA, protein kinase A;
GEF, guanine nucleotide exchange factor
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doi:10.1016/j.febslet.2005.07.080recently, Rap proteins were found to regulate cell junction for-
mation as well. The ﬁrst evidence for involvement of Rap in
the formation of adherens junctions came from genetic studies
in Drosophila melanogaster. Here, loss of the rap1 gene resulted
in asymmetric positioning of cadherins at cell–cell contact
sites, suggesting that Rap may directly modulate cadherin
function [3]. Also, DOCK4, an activator of Rap1, enhances
the formation of adherens junctions, again hinting towards a
role for Rap1 in the regulation of cadherin-mediated cell–cell
adhesion [4]. In addition, another GEF for Rap, C3G, associ-
ates with E-cadherin and regulates the formation of nascent
junctions through Rap [5]. Finally, inhibition of Rap inhibits
E-cadherin function. Interestingly, Epac1 expression in epithe-
lial MDCK cells makes these cells sensitive to cAMP-induced
junction formation. This suggests that also Epac could be in-
volved in the control of junction formation [6].
For endothelial cells it is well established that cAMP stimu-
lates the formation of cell junctions, thereby increasing the
barrier function and the protection against various inﬂamma-
tory mediators. Previously, it was suggested that PKA medi-
ates this cAMP eﬀect. However, inhibition of PKA did not
abolish all cAMP eﬀects, suggesting that Epac maybe involved
in this process as well [7,8]. In keeping with our previous
results that Epac is able to regulate E-cadherin-mediated cell
junction formation [6], we have investigated whether Epac
plays a role in endothelial junction formation by siRNA and
if so whether VE-cadherin is involved in this process. We ob-
serve that in human umbilical vein endothelial cells (HUVEC)
Epac1 is the main mediator of cAMP-induced junction forma-
tion, a process that requires VE-cadherin, and may involve the
formation of cortical actin.2. Materials and methods
2.1. Cell culture and transfections
HUVEC were isolated according to Jaﬀe et al. [9,10] with some mod-
iﬁcations as described and cultured in EBM-2 Bulletkit culture medium
(EBM-2 supplemented with EGM-2 SingleQuots (hEGF, hydrocorti-
sone, fetal bovine serum, VEGF, hFGF-B, R3-IGF-1, ascorbic acid,
GA-1000, heparin)) (Clonetics). Second to fourth passage cells were
used. Cells were cultured on 1% gelatin (Sigma) and experiments were
performed on 7 lg/ml ﬁbronectin (Sigma). 18 h after plating HUVEC
were transfected with or without siRNA oligos (Dharmacon) against
Epac1 (GCACCTACGTCTGCAACAA); (CCATCATCCTGCGA-
GAAGA) or AF6 (GAAUAUAGUGAACCAAAGA) where indi-
cated using Oligofectamine (Invitrogen) according to manufacturers
recommendation. Transfection was repeated after 24 h. Samples were
analyzed 48 h after the second round of transfections. Endothelial cells
with a homozygous null mutation of the VE-Cadherin-gene andblished by Elsevier B.V. All rights reserved.
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herin positive) were described previously [11]. 8CPT-20O-Me-cAMP/
007 (Biolog) was used at a ﬁnal concentration of 100 lM; Forskolin
(Sigma) was used at 10 lM.
2.2. Antibodies
The mouse mAb 5D3 against Epac1 has been described previously
[6]. Epac2 mouse mAb was generated in our laboratory (J. Zhao,
unpublished results). The mouse mAb against the extracellular domain
of human VE-cadherin used were clone TEA 1.31, clone BV9 [12,13]
and Cadherin-5 (Transduction labs). Rap1 polyclonal antibodies (San-
ta Cruz), Cortactin monoclonal antibody (Cell Signaling) and Tubulin
monoclonal antibody (Oncogene) were used.
2.3. Rap1 activation assay
Rap1 activity was assayed as described previously [14]. Brieﬂy, cells
were washed with cold PBS and lysed with buﬀer containing 1% Non-
idet P-40. Lysates were cleared by centrifugation, and active Rap was
precipitated with glutathione–Sepharose beads pre-coupled to a GST
fusion protein of the Ras binding domain of RalGDS. Precipitates
were washed three times with lysis buﬀer and solubilised in SDS sample
buﬀer. A portion of the cell lysate was reserved for analysis of total
Rap1 content. Rap1 was detected using Western blotting with anti-
Rap1 antibodies.
2.4. Permeability assay
Transwell units (6.5-mm diameter, 0.4-lm pore size polycarbonate
ﬁlters, Corning Costar Corporation) coated with ﬁbronectin (7 lg/
mL) were used. Culture medium in the upper and lower compartments
was 100 and 600 lL, respectively, as suggested by the manufacturer.
Cells were cultured for 48–72 h prior to analysis. Cells were incubated
with 007 before addition of ﬂuorescein (FITC)-conjugated dextran
(38900 Da, ﬁnal concentration 1 mg/mL, (Sigma)) to measure perme-
ability, immediately followed by a-thrombin (0.1 U/ml). After
30 min, a 50 lL sample was removed from the lower compartment
and measured using a ﬂuorospectrometer at 492 nm.
2.5. Immunoﬂuorescence
Cells were cultured on ﬁbronectin-coated (7 lg/mL) glass coverslips
(13 mm). After stimulation, cells were ﬁxed with 3.8% formaldehyde,
permeabilised using 0.2% Triton X-100 and blocked with 2% BSA inFig. 1. Epac1/Rap pathway is functional in HUVEC. (A) Expression of Epac
and expression of Epac2 in HUVEC compared with Epac2 expressing INS
monoclonal antibody 5D3 and Epac2 monoclonal antibody (B) Knock-down
Epac1 expression was determined after 48 h by Westernblotting using 5D3. (
activation. Cells were transfected twice with siRNA and after 48 h stimulated
assay. Inhibition of Rap1 activation was also observed with a diﬀerent Epac1PBS. Cells were incubated with indicated antibodies for 1 h and
subsequently incubated with FITC-phalloidin and/or Cy3-labeled
donkey-anti-mouse antibody (Jackson labs) for 1 h. After mounting
the coverslips onto slides, cells were examined using a Zeiss Axiokop2.
Quantiﬁcations were performed using Metamorph software (Universal
Imaging).3. Results
3.1. cAMP-induced Rap1 activation in HUVEC is mediated by
Epac1
To investigate whether and if so, which Epac is functional in
HUVE cells, we ﬁrst tested which of the two Epac proteins,
Epac1 or Epac2, is present. Using monoclonal antibodies to
either Epac1 or Epac2 we only observe a positive signal with
a mAb against Epac1 (Fig. 1A). Epac1 is represented by a dou-
ble band as previously observed in Ovcar3 cells. To investigate
whether both bands represent proteins from the Epac1 gene we
used siRNA to knock-down Epac1. Indeed, both bands disap-
pear indicating that they represent two forms of Epac1
(Fig. 1B). The diﬀerence between the two forms is currently
unclear. Epac is a GEF for the small GTPases Rap1 and
Rap2 and is directly activated by cAMP. To investigate
whether Epac1 is functional in HUVEC we stimulated the cells
with forskolin, a compound that activates adenylate-cyclase,
resulting in an increase in cAMP. In addition we used a cAMP
analog, 8-CPT-2 0o-Me-cAMP (007) that speciﬁcally activates
Epac and not PKA. Both compounds indeed activate Rap1.
This activation is completely inhibited by siRNA against
Epac1, showing that both cAMP- and 007-induced activation
of Rap1 is mediated by Epac1 (Fig. 1C). Time course analysis
revealed that 007 activates Rap1 rapidly. This activation per-
sists for at least 30 min (Fig. 1D). From these results we con-
clude that HUVEC have a functional cAMP-Epac1-Rap1
signaling pathway.1 in HUVEC compared with Epac1 expressing Ovcar3 cells (left panel)
1 cells. Western blots of total cell lysates was probed with the Epac1
of Epac1 by siRNA. HUVEC were transfected twice with siRNA and
C) Eﬀect of knock-down of Epac1 on forskolin and 007-induced Rap1
as indicated for 15 min and Rap1GTP was determined by the pull down
siRNA. (D) Timecourse of Rap1 activation after stimulation with 007.
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reduces endothelial permeability
cAMP is a well established mediator of stimuli that can af-
fect the integrity of the endothelial cell layer by tightening
the junctions between endothelial cells. To investigate whether
activation of Epac results in more robust cell junctions we
stimulated endothelial cells with 007 and stained the cells for
both VE-cadherin and actin. VE-cadherin is one of the critical
and ﬁrst components in the formation of cell junctions.
Whereas in unstimulated cells the junctions are still rather
immature, zipper-like, with small gaps between the cells,
30 min of stimulation with 007 results in much more tightenedFig. 2. Epac1 activation induces junction formation and actin remodeling an
junctions. HUVE cells were treated with or without 007 for 30 min and stai
Cortactin staining of HUVEC upon Epac1 activation. HUVEC were treate
Permeability assay with HUVEC transfected with or without Epac siRNA
permeability of the monolayer was determined with ﬂuorescently labeled dex
addition of dextran and leakage was measured 30 min later. Data shown a
signiﬁcant between the mock-transfected samples as determined by student
junctions. Cells were treated with or without 007 for 30 min prior to treatmen
Bar = 50 lm. (E) 007 inhibits a-thrombin-induced permeability. HUVEC we
ﬂuorescent dextran in the presence or absence of a-thrombin and permeabi
relative increase to that observed in unstimulated cells. Inset represents an en
determined by Students t test (P < 0.05). Data shown are representative of
HUVE cells with a-thrombin and 007 as indicated.junctions. In addition, a clear change of the actin cytoskeleton
is observed from stress ﬁbers spanning the cell body in the
unstimulated cells to ﬁlamentous actin at the cell periphery
in 007-stimulated cells (Fig. 2A).
To further stress the appearance of peripheral ﬁlamentous
actin in 007-stimulated cells we stained the cells for cortactin,
a marker for cortical actin. Clearly, stimulation of HUVEC
with 007 results in a remarkable increase in cortactin staining
at the cell junctions. This increase is largely abolished when the
cells were ﬁrst treated with siRNA against Epac1. Importantly,
also forskolin-induced peripheral cortactin staining is largely
inhibited by siRNA against Epac1, indicating that Epac1,d reduces permeability. (A) Eﬀects of 007 on the actin cytoskeleton and
ned for VE-cadherin and ﬁlamentous actin (F-actin). Bar = 50 lm. (B)
d as indicated for 30 min and stained for cortactin. Bar = 50 lm. (C)
. HUVEC were transfected twice with Epac1 siRNA and after 48 h
tran. Cells were incubated with or without 007 for 30 min prior to the
re representative of three independent experiments. Diﬀerences were
s t test (P < 0.05). (D) 007 inhibits a-thrombin-induced disruption of
t with a-thrombin for 30 min and stained for VE-cadherin and F-actin.
re treated with or without 007 for 30 min previous to the addition of
lity was measured after 30 min. Average permeability was shown as a
largement of the mock treated samples. Diﬀerences were signiﬁcant as
three experiments. (F) Rap1GTP levels were determined after treating
Fig. 2 (continued)
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(Fig. 2B).
Permeability of endothelial cell layers is regulated in part
by the opening and closure of the cell junctions. To investi-
gate whether 007 regulates endothelial permeability in vitro
HUVEC were seeded in transwell plates and permeability
for FITC-dextran was measured. As shown in Fig. 2C, 007
reduced permeability by 30–50% dependent on the experi-
ment. Again, Epac1 siRNA completely abolished the 007 ef-
fect, supporting the notion that Epac1 mediates the 007
eﬀect. Permeability of endothelial cells is strongly induced
by various stimuli, including a-thrombin. Also this eﬀect is
strongly reduced by 007 treatment, as shown both by stain-
ing for VE-cadherin (Fig. 2D) and by measuring cell perme-ability (Fig. 2E). Cell permeability of a-thrombin-treated
cells in the presence of 007 is even much higher than in un-
treated cells. To investigate whether this diﬀerence may cor-
relate with Rap1 activity, we measure a-thrombin-induced
Rap1 activation in the presence and absence of 007. How-
ever, we did not observe a-thrombin-induced Rap1 activa-
tion, whereas 007-induced Rap1 activation is similar in
a-thrombin-treated cells compared to untreated cells
(Fig. 2F). From these results we conclude that in HUVEC
activation of Epac1 stimulates the formation of cell junctions
and reduces cell permeability. In addition, we show that
Epac1 signaling antagonizes a-thrombin-induced cell
junction disruption probably at a level downstream from
Rap1.
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VE-cadherin
One of the ﬁrst steps in junction formation is a calcium
dependent, homotypic interaction between VE-cadherin
between two neighboring cells. To investigate whether VE-
cadherin is required for 007 induced eﬀects on cell junction
formation we used VE-cadherin null mouse cells immortalized
with polyoma mT. These cells still form junctions although at
a slower rate and with an increased permeability. Importantly,
treatment with 007 did not aﬀect the permeability of these
cells, whereas cells rescued with a mammalian VE-cadherin
did show a consistent 20% decrease in permeability after
treatment with 007 (Fig. 3A). This diﬀerence is not due to
the diﬀerences in activation of Rap1 by 007, since in both cell
types 007 induced similar Rap1 activation (Fig. 3B). We
therefore conclude that VE cadherin is an essential mediator
of Epac1-induced cell junction formation.3.4. Actin remodeling by 007 is independent of junction
formation
Since the actin cytoskeleton and adherens junctions are inti-
mately linked we investigated whether the eﬀects we observed
on the actin cytoskeleton are dependent on junction formation.
To investigate whether VE-cadherin is required for the actin
remodeling, we investigated whether the remodeling also oc-
curs in VE-cadherin null cells. Unfortunately, both in the
VE-cadherin positive and VE-cadherin null cells we could
not observe 007-induced actin remodeling (data not shown).Fig. 3. 007-induced reduction of endothelial permeability is dependent
on VE-cadherin. (A) Endothelial permeability was measured in mouse
VE-cadherin null cells and in mouse VE-cadherin null cells retrans-
formed with VE-cadherin. Cells were treated with or without 007 for
5 min prior to the addition of ﬂuorescent dextran. Leakage was
measured after 30 min. Diﬀerences in VE-cadherin positive cells were
signiﬁcant as determined by Students t test (P < 0.05) (B) VE-cadherin
null cells do not have an impaired Rap1 activation. Indicated cell-lines
were stimulated with 007 for the indicated timepoints and Rap1GTP
was measured by the pull down assay.As an alternative approach we used the VE-cadherin-speciﬁc
blocking antibody BV9. Binding of BV9 to VE-cadherin causes
the disappearance of VE-cadherin from cell–cell contacts [15].
Incubation of HUVEC with BV9 did not aﬀect 007-induced
actin rearrangements that resembled the changes observed
within an intact monolayer (Fig. 4A), suggesting that 007-in-
duced actin rearrangements is not due to VE-cadherin-medi-
ated cell junction formation. To exclude the possibility that
cell–cell adhesion is still somehow involved in 007-induced ac-
tin rearrangements we treated a sparse culture of HUVEC with
007. Importantly, single cells did show rearrangement of the
actin cytoskeleton similar to that observed within a monolayer
of HUVEC, i.e., a decrease in medial stress ﬁbers and an in-
crease in peripheral stress ﬁbers or cortical actin (Fig. 4B).
Quantiﬁcation of these actin rearrangements in multiple cells
showed a 30% increase in cortical/medial-actin ratio upon
007 treatment (Fig. 4C). From these results we conclude that
the observed 007-induced actin rearrangements are indepen-
dent of cell junction formation.4. Discussion
In this paper, we show ﬁrstly that HUVEC express the
cAMP-responsive Rap1 GEF, Epac1 predominantly over
Epac2 and by siRNA that cAMP-induced Rap1 activation is
mediated by Epac1. Secondly, treatment of HUVEC with
007 results in morphologically more tight cell junctions, a rear-
rangement of the actin cytoskeleton from stress ﬁbers spanning
the cell body in unstimulated cells to more cortically located
ﬁlamentous actin after 007 stimulation. Again this eﬀect was
abolished by siRNA against Epac1. Thirdly, we found that
VE-cadherin is required for Epac-induced cell junction forma-
tion and ﬁnally we found that Epac activation results in a rear-
rangement of the actin cytoskeleton independently of junction
formation. While these studies were in progress three papers
were published which collectively come to a similar conclusion
[16–18]. In these studies, a role for Epac in endothelial cell
junction formation was demonstrated using the Epac speciﬁc
analog 8CPT-2 0O-Me-cAMP (007). In all these studies, 007
was found to tighten cell junctions and to increase the barrier
function of an endothelial monolayer in vitro. Our studies ex-
tend these ﬁndings by showing that Epac1, and not Epac2, is
mediating this eﬀect. This conclusion is based on the observa-
tions that we only observe clear Epac1 expression in HUVEC
and more importantly, siRNA against Epac1 completely abol-
ished 007-induced Rap1 activation and 007-induced eﬀects on
cell junctions.
The mechanism by which Epac1 regulates endothelial cell
junctions is still largely elusive, but it is clear that VE-cadherin
plays a critical role in this process. Firstly, 007 treatment
results in more active VE-cadherin at the cell surface [17]
and secondly, 007 is unable to increase endothelial barrier
function in cells lacking VE-cadherin (this paper). This result
is compatible with previous results showing that the Rap1 sig-
naling pathway controls cell junction formation in epithelial
cells through E-cadherin [3,5,6]. In addition, it is clear that
Epac induces a rearrangement of the actin cytoskeleton, from
stress ﬁbers that span the cell body to cortical actin, and the
recruitment of the cortical actin-binding protein cortactin to
the cell junctions. Importantly, cell junction formation is not
Fig. 4. Actin remodeling by 007 is not dependent on junctions. (A) The eﬀect of blocking VE-cadherin on 007 induced actin remodeling. BV9, a VE-
cadherin blocking antibody, and a control antibody were added to the HUVEC for 7 h and were subsequently incubated with 007 for 30 min before
cells were ﬁxed and stained for F-actin. Bar = 50 lm. (B) Actin remodeling in the absence of junctions. HUVEC were plated at 1 · 104 cells/12 well.
After 24 h cells were treated with or without 007 for 30 min. Single cells were examined using immunoﬂuorescence for F-actin. Bar = 10 lm. (C)
Quantiﬁcation of actin remodeling in single cells. Intensity of F-actin staining of single cells from (B) was measured over an imaginary line through
the cell. The average intensity of the outer quarters of the line was divided over the inner two quarters. Average values and SE of 40 cells are shown.
(P < 0.0001).
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tion of junctions by calcium depletion or VE-cadherin-speciﬁc
blocking antibodies is not interfering with actin remodeling
and actin remodeling is observed in sparse cultures [16], (this
paper). This opens the attractive hypothesis that the eﬀect of
Epac on cell junction formation is mediated by Epac-induced
cytoskeletal rearrangements. Indeed a number of proteins that
are involved in the organization of the actin cytoskeleton have
been implicated as downstream eﬀectors of Rap and thus
Epac. These proteins include Vav and Tiam, two GEFs for
Rac, Arap3, a GTPase activating protein for Rho and Arf,
and Riam, a proﬁling binding protein [19–21]. More recently
AF-6 was implicated in the Rap1 dependent regulation ofE-cadherin endocytosis [22]. Also several studies have impli-
cated Rap signaling upstream from CDC42 [23,24]. Whether
these proteins are involved in the observed Epac eﬀects in
HUVEC is currently unclear. Intriguingly, 007 was found to
inhibit a-thrombin-induced Rho activation, but not basal
Rho activity [16]. Indeed, a-thrombin reduces barrier function
of endothelial cells by activation of Rho and thus inhibition of
Rho by Epac signaling counteracts the a-thrombin-eﬀect [25].
Since Epac has apparently no eﬀect on basal Rho activity, a
diﬀerent mechanism may be used by Epac to control junction
formation.
Vascular leakage as a consequence of a failure in endothelial
barrier function often results in serious pathological conditions,
4972 M.R.H. Kooistra et al. / FEBS Letters 579 (2005) 4966–4972including edema and chronic inﬂammation. The ﬁndings that
activation of Epac1 can restore endothelial barrier function
makes Epac1 a promising target for drugs to restore endothe-
lial integrity. We are currently testing whether indeed the
cAMP analog 007 has this protective eﬀect.
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